RxDoctor Payments Data

Amy Voigt, MD

Neurology · Metairie, LANPI 1003088915

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $103,589 of the $126,896 with a category attached, or 81.6%. 38 manufacturers reported payments, led by AbbVie at 49.8% of the total. Among neurology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$126,896in general payments, 2019–2025

Across 734 payments — averaging $172.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$63K
  • Amgen$24K
  • Teva Pharmaceuticals USA, Inc.$12K
  • Biohaven Pharmaceutical Holding Company Ltd.$11K
  • Biohaven Pharmaceuticals, Inc.$8K
  • Lilly USA, LLC$5K
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$3,7503%
  • Speaking & faculty fees$103,58982%
  • Travel & lodging$7,1126%
  • Food & beverage$12,35410%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$126,896 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,580
Medicare patients
29
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe121$89,605
BotoxOnabotulinumtoxina68$86,172
UbrelvyUbrogepant54$82,062
Nurtec OdtRimegepant Sulfate46$81,932
QuliptaAtogepant44$51,090
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen30$50,425
Emgality SyringeGalcanezumab-Gnlm31$38,329
Ajovy AutoinjectorFremanezumab-Vfrm46$32,319
Emgality PenGalcanezumab-Gnlm22$15,764
Butorphanol Tartrate65$10,867
Sumatriptan Succinate141$6,397
Sumatriptan29$4,822
VyvanseLisdexamfetamine Dimesylate11$4,151
Chlorpromazine Hcl45$3,593
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine151$3,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$63,212$219,323166 claims
PfizerNurtec Odt$296$81,93246 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$117$4,15111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.

Other neurology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →